论文部分内容阅读
目的从影响细胞间粘附分子-1(ICAM-1)表达的角度,探讨厄贝沙坦对实验性糖尿病大鼠肾脏的保护作用及其可能机制。方法SD健康大鼠24只,随机分为对照组、模型组、药物组,每组8只。链脲佐菌素(STZ)诱导糖尿病大鼠模型,药物组大鼠每日给予厄贝沙坦150mg/kg体重灌胃,持续6周。6周后抽血测血糖(BG),糖化血红蛋白(HbA1c),尿素氮(BUN),肌酐(Scr);测定24h尿微量白蛋白(mAlb),计算尿白蛋白排泄率(UAER)。处死SD大鼠,取其肾脏,用免疫组化方法检测ICAM-1。结果模型组与药物组的BG、HbA1c、BUN、Scr都高于对照组,上述指标在模型组与药物组之间差异无统计学意义。模型组UAER高于对照组,而药物组则低于模型组。药物组ICAM-1蛋白表达量低于模型组。结论厄贝沙坦对实验性糖尿病大鼠的肾脏有保护作用,其机制可能与抑制ICAM-1在肾脏的表达有关。
Objective To explore the protective effect of irbesartan on the kidney of experimental diabetic rats and its possible mechanism from the perspective of affecting the expression of intercellular adhesion molecule-1 (ICAM-1). Methods Twenty-four SD healthy rats were randomly divided into control group, model group and drug group, with 8 rats in each group. Streptozotocin (STZ) -induced diabetic rat model, the drug group rats were given irbesartan 150mg / kg body weight intragastrically for 6 weeks. After 6 weeks, blood glucose (BG), HbA1c, BUN and Scr were measured; urinary albumin excretion rate (UAER) was calculated after 24h urine microalbumin (mAlb) was measured. The SD rats were sacrificed and their kidneys were taken out. ICAM-1 was detected by immunohistochemistry. Results The levels of BG, HbA1c, BUN and Scr in the model group and the drug group were higher than those in the control group. There was no significant difference in the above parameters between the model group and the drug group. UAER in the model group was higher than that in the control group, while the drug group was lower than the model group. ICAM-1 protein expression in the drug group was lower than that in the model group. Conclusion Irbesartan has a protective effect on the kidney of experimental diabetic rats, which may be related to the inhibition of ICAM-1 expression in the kidney.